Clinical course and prediction of survival in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, vol.183, pp.431-440, 2011. ,
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am J Respir Crit Care Med, vol.198, pp.44-68, 2018. ,
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, vol.377, pp.1760-1769, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00873255
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014. ,
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function, Eur Respir J, vol.48, pp.843-851, 2016. ,
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials, Respir Med, vol.113, pp.74-79, 2016. ,
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis Across Prespecified Subgroups in INPULSIS, Am J Respir Crit Care Med, vol.193, pp.178-185, 2016. ,
Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views, Respiration, pp.1-11, 2018. ,
An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP), Respiration, vol.94, pp.408-415, 2017. ,
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment ,
, Eur Respir J, vol.48, p.1809, 2016.
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials, Eur Respir J, vol.47, pp.243-253, 2016. ,